Medical/Pharmaceuticals

Eyes that photosynthesise: NUS scientists plant a cure for dry eye disease

A nanosized extract of the plant thylakoid grana — the molecular engine behind photosynthesis — is transplanted into the eye's corneal cells, producing a key protective molecule when exposed to ambient light, opening a new front against dry eye disease SINGAPORE, May 15, 2026 /PRNewswire/ -- Wha...

2026-05-16 11:14 1136

Atisama Therapeutics Advances RB042 into Multiple Ascending Dose cohorts of Phase 1 Trial and Appoints Bernard Coulie as Chair of the Board

* RB042 Phase 1 trial advances into multiple ascending dose study cohorts, demonstrating safety and tolerabilityto date. * Dr. Coulie brings more than 25 years of international biopharma leadership and deep expertise in pulmonary disease to the Atisama Board of Directors. MELBOURNE, Australia...

2026-05-15 22:25 3628

Racura Oncology Announces Positive Safety Review Committee Recommendation in ongoing CPACS Clinical Trial

Safety Review Committee (SRC) gives Racura Oncology a recommendation to continue the Cardioprotection and Anticancer Synergy (CPACS) study in advanced solid tumor patients SYDNEY, May 15, 2026 /PRNewswire/ -- Racura Oncology, an Australian Phase 3 stage clinical biopharmaceutical company, today ...

2026-05-15 19:06 2650

Phase II Data from a Randomized Double-Blind Trial of Ligufalimab (Anti-CD47) Combination Therapy in Frontline AML Published at EHA 2026

HONG KONG, May 15, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that compelling results from its randomized, double-blind, placebo-controlled Phase II trial (AK117-206) of ligufalimab (AK117) will be presented as an oral presentation at the 2026 European ...

2026-05-15 15:43 2401

SN BioScience Doses First Patient in Phase 1b/2 Clinical Trial of 'SNB-101'

SEONGNAM, South Korea, May 14, 2026 /PRNewswire/ -- SN BioScience Inc., a clinical-stage biotechnology company based in South Korea, announced today that it has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB-101 (API: SN-38), a nanoparticle anticancer ag...

2026-05-15 07:03 1985

POMDOCTOR LIMITED Announces Fiscal Year 2025 Financial Results

GUANGZHOU, China, May 14, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases in China, today announced its financial results for the fiscal year ended December 31, 2025. Mr. Zhenyang Shi, Chairman a...

2026-05-15 04:30 3455

DeepQure Reports Encouraging Clinical Data from World's First Extravascular RDN System at AUA 2026

WASHINGTON, May 14, 2026 /PRNewswire/ -- DeepQure, a clinical-stage medical device company, announced the completion of its featured presentation at the American Urological Association (AUA) Innovation Nexus Forum, held during the AUA Annual Meeting. DeepQure was selected to present the clinical ...

2026-05-15 02:30 1905

OnCusp Therapeutics Appoints Anthony Kim as Chief Financial Officer

PRINCETON, N.J., May 14, 2026 /PRNewswire/ -- OnCusp Therapeutics, Inc., a clinical-stage biopharmaceutical company developing differentiated oncology therapies designed to translate cutting-edge innovation into clinically meaningful outcomes for patients, today announced the appointment of Antho...

2026-05-14 21:00 1944

Yuyu Pharma's Mervyn's Petcare Launches Cat Dental Care Treat on Amazon, Marking First Overseas Pet Health Push

SEOUL, South Korea, May 14, 2026 /PRNewswire/ -- Mervyn's Petcare, the U.S. subsidiary of Korea-based Yuyu Pharmaceutical (KRX: 000220), has launched its first cat dental care nutritional supplement product, "Ari's Purrfect Dental Bites

2026-05-14 21:00 3561

China Pharma Holdings, Inc. States It Knows of No Events That Could Have Caused Unusual Market Activity

HAIKOU, China, May 14, 2026 /PRNewswire/ -- China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma" or the "Company"), a fully-integrated specialty pharmaceuticals company in China, today announced that, in view of the unusual market activity in the common stock of China Pharma on May 1...

2026-05-14 20:56 3488

VARON Celebrates Older Americans Month by Supporting Healthy Aging and Independence

NEW YORK, May 14, 2026 /PRNewswire/ -- This May, in honor of Older Americans Month, VARON , a leading provider of oxygen and respiratory care so...

2026-05-14 19:06 1497

So-Young to Report First Quarter 2026 Financial Results on May 22, 2026

BEIJING, May 14, 2026 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the leading aesthetic treatment platform in China connecting consumers with online services and offline treatments, today announced that it will report its financial results for the first...

2026-05-14 17:00 2087

EBT Medical and NinaMED Announce US$13.75M Financing to Advance Licensed NiNA System® for Overactive Bladder

* US$13.75M financing completed to accelerate clinical pathway and global commercialisation * Establishment of NinaMED Pty Ltd, a new Australian medtech company * NinaMED Pty Ltd secures a license from EBT Medical for exclusive global rights to NiNA System®, a non‑invasive, at‑home OAB thera...

2026-05-14 13:03 1955

METiS TechBio, the World's First Publicly Listed AI-Powered Drug Delivery Company, Debuts on the Hong Kong Stock Exchange, "The SpaceX of Pharmaceuticals" Ushers in a New Era of Biopharmaceuticals

HONG KONG, May 13, 2026 /PRNewswire/ -- METiS TechBio (7666.HK), a tech-bio company focused on AI-powered nanodelivery innovation, today successfully listed on the Hong Kong Stock Exchange (HKEX), becoming the world's first publicly listed AI-powered drug delivery company and the first AI-powered...

2026-05-14 10:09 2494

Elabscience® Launches Self-Developed PolyHRP-Streptavidin Conjugate for Low-Abundance Biomarker Detection in ELISA

HOUSTON, May 13, 2026 /PRNewswire/ -- Elabscience® Bionovation Inc. ("Elabscience®" or "the Company") today announced the launch of its self-developed PolyHRP-Streptavidin conjugate, a signal amplification reagent designed to improve enzyme-linked immunosorbent assay (ELISA) sensitivity for low-...

2026-05-14 00:00 2574

Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility

* The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. * This cutting-edge suite will significantly enhance the company's ability to support global payload-linke...

2026-05-13 22:45 2934

High-Trend International Group Announces Pricing of $15 Million Registered Direct Offering with Global Institutional Investors

NEW YORK, May 13, 2026 /PRNewswire/ -- High-Trend International Group (NASDAQ: HTCO) ("HTCO" or the "Company"), a global ocean transportation company, today announced that it has entered into securities purchase agreements with global institutional investors for the purchase and sale of 2,307,700...

2026-05-13 20:00 2953

New Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

HONG KONG, May 12, 2026 /PRNewswire/ -- A major new clinical study, SUPER 2, has been published in Nature Communications, reporting that Efsubaglutide Alfa, a long-actingGLP-1 receptor agonist, significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metf...

2026-05-13 11:47 2628

WuXi Biologics Included in 2026 Dow Jones Best‑in‑Class World Index and Emerging Markets Index

SHANGHAI, May 12, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that, in recognition of its continued efforts and exceptional performance in advancing sustainability, the Company has been included i...

2026-05-13 11:33 2345

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

SAN FRANCISCO and SUZHOU, China, May 12, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2026-05-13 08:00 2689
12345 ... 257